"2022 was a pivotal year characterized by intensive strategic work. Much progress has been made since our IPO just two years ago, not least with the presentation of positive results from multiple investigator-initiated studies with uTRACE®. During 2022 we updated our clinical strategy, and we are now pursuing four promising indications with uTRACE® - brain cancer, prostate cancer, head- and neck cancer and neuroendocrine tumours.
The new strategy enables
An important part of our new strategy is to establish synergistic partnerships which could build further value in our business. During discussions with potential partners, we have seen a genuine interest in
As we continue to accelerate our development and execute our strategy,
Last but not least
January -
- Net sales amounted to 0
(0) DKK -
Operating profit/loss amounted to -18,962,317
(-11,401,890) DKK -
Profit/loss before taxes amounted to -19,488,453
(-11,781,790) DKK -
Profit/loss for the year amounted to -18,349,187
(-11,115,350) DKK -
Total assets amounted to 59,667,946
(77,915,451) DKK - Equity ratio amounted to 96,5 (97,4) %.
-
Earnings per share amounted to -0.92
(-0.56) DKK
Change in accounting policy
The company has changed its accounting policy in the following areas:
The company wants to adapt and use the International Financial Reporting Standards (IFRS) from the fiscal year 2023. Recognition of development costs as expense in the in the income statement previously, development costs were capitalized in the balance sheet. In future, development costs will be recognised as expenses in the income statement as management believes that this will provide a fairer presentation and it will be more comparative with other companies in the Pharma industry. The comparative figures have been restated in accordance with the new accounting policy. The changes in accounting policy has a negative impact of
Except for the areas mentioned above, the accounting policies have been applied consistently with the previous year and has no cash impact.
Highlights from 2022
January 10 : Management attended J.P. Morgan 40th Healthcare Conference.
January 18 : Company Investor Presentation at the SEB Nordic Healthcare Seminar 2022.
January 27 : Announced positive results from an investigator-initiated phase II study using uTRACE® in accurate diagnosis of patients with neuroendocrine tumors
February 10 :Curasight announced that the Company has signed and completed an agreement to acquire the early-stage R&D companyTRT Innovations ApS .Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.
February 23 :Curasight announced that the Company has expanded its clinical programs with two additional indications - Neuroendocrine tumors (NET) and head and neck cancer.
April 12 :Curasight gave notice of the Annual General Meeting 2022 to be held onApril 27, 2022 , at the Company's premises.
April 22 :Curasight announced that the United States Patent and Trademark Office has grantedCurasight's United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.
April 25 :Ulrich Krasilnikoff andAndreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.
April 27 :Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company's website.
May 18 :Ulrich Krasilnikoff andAndreas Kjær gave an update on the company's strategy at Kapital Partner's Life Science Seminar.
June 7 :Curasight issued a total of 956,770 warrants for the purpose of launching the Company's long-term incentive program covering the Company's Board of Directors, Executive Management and other key employees.
June 24 :Curasight announced that a transaction with shares inCurasight A/S was made by managerial employee in the period 9 -10 June 2022 .Hanne Damgaard Jensen (Chief Development Officer) bought a total of 16.400 shares.Hanne Damgaard Jensen total holdings inCurasight A/S after the purchase of the shares is 20,000 shares.
June 30 :Curasight announced that the investigator-initiated phase II study using uPARPET in brain cancer had completed the inclusion of patients. First data from the study is expected to be published during H2 2022.
August 25 :Ulrich Krasilnikoff andAndreas Kjær presented the company and the Q2 2022 report atHC Andersen Capital .
September 4 :Curasight announced that the company's CDOHanne Damgaard Jensen had purchased 7,600 shares at an aggregated volume price of97,964 DKK onNovember 1, 2022 .Hanne Damgaard Jensen total holdings inCurasight A/S after the purchase of the shares is 35,000 shares.
October 13 :Curasight announced that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT®) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.
November 21 :Ulrich Krasilnikoff andAndreas Kjær presented the company and the strategy at SEB Healthcare Seminar 2022.
November 28 :Ulrich Krasilnikoff andAndreas Kjær presented the company and the Q3 2022 report atHC Andersen Capital .
For more information regarding
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com
https://news.cision.com/curasight/r/annual-report-for-the-fiscal-year-2022,c3721408
https://mb.cision.com/Main/19744/3721408/1867915.pdf
(c) 2023 Cision. All rights reserved., source